Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

The Gates Foundation committed $2.5 billion through 2030 to support dozens of different approaches for improving women’s ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...

Vertex Pharmaceuticals stock was among the worst performer in the S&P 500 index early Tuesday after the drugmaker said it ...